Annual report [Section 13 and 15(d), not S-K Item 405]

BUSINESS COMBINATION (Details Narrative)

v3.26.1
BUSINESS COMBINATION (Details Narrative) - USD ($)
12 Months Ended
Mar. 04, 2025
Dec. 31, 2025
Dec. 31, 2024
Jul. 29, 2025
BUSINESS COMBINATION        
Pro forma revenue $ 795,454 $ 797,244 $ 803,119  
Pro forma earnings   $ 661,498    
Retention description amounts equal $400,000 of 50% of the Net Sales (as defined in the APA) of Lucemyra and 50% of the Net Distributable Profits (as defined in the APA) of the generic version of Lucemyra      
Common stock shares issued 500,000 500,000 9,374  
Closing market price $ 0.31 $ 0.31    
Common stock purchase 500,000      
Exercise price $ 1.00     $ 0.35
Fair value of stock issued   $ 153,500    
Royalty payments   108,260    
Upfront purchase price $ 400,000 $ 392,441    
Discounted at the risk-free rate   4.04%    
Discounted at required metric risk premium   24.09%    
Acquisition-related costs   $ 528,622    
Pro forma adjusted amount   $ 528,622